GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

OBJECTIVE: Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2 diabetes, and transient GLP-1 administration improved cardiac function in humans after acute myocardial infarction (MI) and percutaneous revascularization. However, the consequences of GLP-1R activation before isc...

Descripción completa

Detalles Bibliográficos
Autores principales: Noyan-Ashraf, Mohammad Hossein, Momen, M. Abdul, Ban, Kiwon, Sadi, Al-Muktafi, Zhou, Yu-Qing, Riazi, Ali M., Baggio, Laurie L., Henkelman, R. Mark, Husain, Mansoor, Drucker, Daniel J.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2009
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661586/
https://www.ncbi.nlm.nih.gov/pubmed/19151200
http://dx.doi.org/10.2337/db08-1193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661586/
https://www.ncbi.nlm.nih.gov/pubmed/19151200
http://dx.doi.org/10.2337/db08-1193

Ejemplares similares